A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

Trial Profile

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ExpeditionPRO
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jun 2017 Status changed from active, no longer recruiting to discontinued as Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to patients with prodromal AD as defined by the study protocol.
    • 10 Jun 2017 Biomarkers information updated
    • 23 May 2017 This trial was discontinued in Poland (end date: 2017-05-08), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top